Fenwick represented Day One Biopharmaceuticals (Nasdaq: DAWN), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, in its pending acquisition by Servier, an independent international pharmaceutical group.
Under the terms of the merger agreement, Servier will commence a cash tender offer to acquire all of the issued and outstanding shares of Day One’s common stock for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2026. More information can be obtained from Day One’s announcement.
The Fenwick transaction team included corporate partners Effie Toshav, Doug Cogen, David Michaels, Rob Freedman and Julia Forbess and associates Rob O’Connor, Arielle Trapp, Brandon Ho, Phillip Craig, Kennedii Brock and Guy Rotstein; technology transactions partner Stefano Quintini, counsel Amy Manning, and associates Adine Mitrani, Monika Petkova and Rob Ferrari; trademark partner Connie Ellerbach and associate Jennifer Liem; privacy and cybersecurity partner Ana Razmazma, counsel Melanie Jolson and associate Natalie Kim; executive compensation partner Marshall Mort and associates Jonathan Stephenson, Rachel Coffey and Melita Chan; antitrust partner Tom Ensign, counsel Meredith Mommers and associate Susan Lee; healthcare regulatory partner Jennifer Yoo and associate Santino Labate; tax partner William Skinner and associate Kris Hatch; and trade and national security partner Robert Slack and associate Brooklynn Moore.